• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Gardasil vaccine demonstrates immunogenic response at 10-year follow-up

byMatthew Lin, MDandLeah Carr, MD
November 22, 2017
in Infectious Disease, Pediatrics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. A 3-dose regimen of 4-valent human papillomavirus (4vHPV) vaccine administered between the ages of 9-15 years of age was shown to be immunogenic, clinically effective, and without significant adverse effects throughout a 10-year follow-up period.

 2. Immunogenic response was most robust when the vaccine was administered during the preadolescent period when compared to the adolescent period.

 Evidence Rating: 1 (Excellent)

 Study Rundown: Human papillomavirus (HPV) infection causes cervical cancer and genital warts. While the HPV family is comprised of 35 strains, types 16 and 18 are responsible for approximately 70% of cervical cancers and HPV-6 and -11 are responsible for 90% of genital warts. In 2007, Gardasil, or the 4vHPV vaccine, was licensed to prevent cervical, vulvar, vaginal, and anal cancer caused by HPV-16 and -18, and genital warts caused by HPV-6 and -11. In this study, researchers provide 10-year long-term follow-up data on 4vHPV vaccine effectiveness, immunogenicity, and safety. In the base study, 1661 sexually inactive male and female subjects between the ages of 9-15 years of age were randomized to an early vaccine group (EVG) who received a 3-dose course of 4vHPV vaccine or to a group given placebo. The placebo group then were then offered the vaccine at the base study’s conclusion using the same dosing schedule. This subset of the placebo group were considered to be in a catch-up vaccine group (CVG). Evaluation of HPV geometric mean titers showed immunogenicity in all vaccine recipients at 10-year follow-up, with a more robust response occurring in patients who had been vaccinated at a younger age. Evaluation of seropositivity using the chemiluminescence immunoassay (cLIA) and IgG luminescence assay (IgG LIA) at approximately 10-year follow-up showed that the majority of subjects remained seropositive for all strains, with HPV-18 having the lowest seropositivity rates. No adverse effects were noted at between 8 to 10 years of follow-up. Limitations included lack of control group and lack of assessment for anal or oropharyngeal sequelae of HPV infection throughout follow-up. This data shows that the 4vHPV vaccine is immunogenic and clinically effective 10 years after administration.

Click to read the study, published today in Pediatrics

Relevant Reading: Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial

RELATED REPORTS

The 2 Minute Medicine Podcast Episode 54

COVID-19 vaccination and infection not associated with increased risk of congenital anomalies

The Scan by 2 Minute Medicine®: Kate Middleton’s Hair: Chemo Mysteries, MRI Screening: Is It Useful?, Biden’s COVID Amid Variant Surge, Avoiding Microplastics

 In-Depth [prospective cohort]: A total of 1245 subjects (EVG = 821; CVG = 424) were enrolled initially in this study, and a total of 803 subjects completed the 10-year post-vaccination follow-up (EVG = 525, CVG = 275). Immunogenicity was measured through serum antibody geometric mean titers (GMTs) and percent seropositivity to HPV-6, 11, 16 and 18. Clinical effectiveness was measured by HPV-6, 11, 16 and 18-related disease or persistent infection. In terms of immunogenicity, in both cohorts, antibody responses peaked at month 7 and persisted over the 10-year follow-up period. However, in comparison to adolescents (13-15 years), preadolescents (9-12 years) had 38-64% higher GMTs at month 7, which remained 16-42% higher at 10 years. Seropositivity for HPV-6, -11 and -16 for male and female subjects using the cLIA assay or IgG LIA assay was >87% response for all subtypes. Serpositivity for HPV-18 was the lowest, ranging from 61.4% (95%54.6-67.8, cLIA assay) to 78.5% (95%CI 72.2-83.6, LIA assay) for girls and 59.6% (95%CI 52.5-66.7, cLIA assay) to 77% (95%CI 70.5-82.7, LIA assay) for boys. With respect to clinical effectiveness, no disease was observed in the form of genital warts and/or genital precancers. Of note, oropharyngeal and anal disease endpoints were not assessed in follow-up. A total of 10 cases of persistent infection (≥6 months) were detected throughout the 10-year follow-up: 4 cases of HPV-16 in girls and 6 cases of HPV-6 and -16 in boys. Among girls and boys, nonvaccine HPV types were responsible for 151 and 53 cases of persistent infection, respectively.

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adolescent medicineHuman Papilloma Virus (HPV)vaccination
Previous Post

Providing unlimited, immediate access to opioid agonist therapy to people with opioid use disorders could save billions and improve outcomes

Next Post

Study suggests testing certain protein combinations can enhance sensitivity of fecal immunochemical test used in colorectal cancer screenings

RelatedReports

The 2 Minute Medicine Podcast Episode 15
2MM Podcast

The 2 Minute Medicine Podcast Episode 54

March 21, 2025
Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity
Infectious Disease

COVID-19 vaccination and infection not associated with increased risk of congenital anomalies

July 26, 2024
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Kate Middleton’s Hair: Chemo Mysteries, MRI Screening: Is It Useful?, Biden’s COVID Amid Variant Surge, Avoiding Microplastics

July 23, 2024
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Infectious Disease

SARS-CoV-2 vaccination side effects associated with increased neutralizing antibodies

June 27, 2024
Next Post
Development of a risk index for colorectal cancer screening

Study suggests testing certain protein combinations can enhance sensitivity of fecal immunochemical test used in colorectal cancer screenings

Ultrasound screening for AAAs has no effect on all-cause mortality

2 Minute Medicine Rewind November 20, 2017

Study reveals suburban clinicians’ perspectives on screening for food insecurity

CFTR modulation therapy improves predicted FEV1 in patients with heterozygote residual function cystic fibrosis

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
  • 2 Minute Medicine Rewind June 30, 2025
  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.